Lawsuit Filed Over Kidney and Bone Injuries From Truvada, Viread and Other Gilead HIV Drugs

A product liability lawsuit filed by more than 40 plaintiffs claims that side effects of Gilead’s HIV combination therapy drugs, such as Truvada, Viread, Atripla, Complera and Stribild, exposed users to an unnecessary risk of serious kidney and bone injuries.

The complaint (PDF) was filed in the U.S. District Court for the Northern District of California on July 1, alleging that Gilead, Inc. knew about the toxic risks associated with the medications, yet withheld safer and less toxic versions as part of a scheme to continue profiting from the sale of the high-priced HIV drugs until generic competitors were introduced.

Each of the medications contain the compound tenofovir disoproxil fumarate (TDF), which is known to be toxic to the bones and kidneys. However, the lawsuit alleges that Gilead had already discovered a safer compound, tenofovir alafenamide fumarate (TAF), which is just as effective, but far less toxic since it can be taken at much smaller doses.


Were you or a loved one prescribed Truvada or other HIV drugs?

Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries. Lawyers are actively reviewing cases for individuals who have suffered injuries.

Learn More About this Lawsuit See If You Qualify For Compensation

Instead of developing and releasing the safer products, the lawsuit alleges that Gilead engaged in a plan to maximize products by delaying the new drugs until the original products faced generic competition. The drug maker then marketed the TAF-based HIV drugs, which include Descovy, Genvoya and others, which are still under patent protection.

Gilead now markets the newer treatments as safer, and has extended its monopoly over HIV treatments in the United States. However, the scheme came at the expense of thousands of users of the drug, who have been left with devastating bone problems and kidney injuries.

“In addition to withholding safer designs, Gilead failed to adequately warn physicians and patients about the risks and safe use of TDF. Gilead provided only the weakest, inadequate warnings to doctors and patients about the need for frequent monitoring of all patients for TDF-associated kidney and bone damage—preventing doctors from detecting early signs of TDF toxicity,” the lawsuit states. “Gilead provides stronger monitoring warnings to physicians and patients in the European Union (EU) than it does in the United States for the exact same TDF products.”

The lawsuit presents claims of design defect, failure to warn, negligence, gross negligence, fraud by omission, breach of warranty, and violation of state consumer protection and product liability laws in New Jersey, Ohio, Arizona, Colorado, Maryland and Massachusetts. The plaintiffs seek compensatory and punitive damages.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks
Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks (Posted today)

Women who used Johnson's Baby Powder around their genitals for feminine hygiene purposes now live in fear of developing ovarian cancer, according to the class action lawsuit seeking medical monitoring for future diagnoses

More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing
More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing (Posted yesterday)

A bundled complaint of about 9,600 Suboxone lawsuits were filed in federal court on Friday, ahead of the two-year anniversary of the FDA requiring tooth decay label warnings on the opioid treatment film strips, which is also a deadline for filing a civil complaint in many states.